



PTO/IS/B/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/555,860	
			Filing Date	November 1, 2005	
			First Named Inventor	Christopher P. Holmes	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	4	Attorney Docket Number	04279/100M213-US1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)				
	USPD1	US-6,858,630		02-22-2005	Luengo et al.	
	USPD2	US-6,784,154		08-31-2004	Westenfelder	
	USPD3	US-6,783,965		08-31-2004	Sherman et al.	
	USPD4	US-6,660,843		12-09-2003	Feige, et al.	
	USPD5	US-6,583,272		06-24-2003	Bailon	
	USPD6	US-6,576,235		06-10-2003	Williams et al.	
	USPD7	US-6,552,167		04-22-2003	Rose	
	USPD8	US-6,552,008		04-22-2003	Duffy et al.	
	USPD9	US-6,531,121		03-11-2003	Brines, et al.	
	USPD10	US-6,506,362		01-14-2003	Dower et al.	
	USPD11	US-6,498,155		12-24-2002	Luengo et al.	
	USPD12	US-6,489,293		12-03-2002	Sytkowski, et al.	
	USPD13	US-6,465,430		10-15-2002	Dower et al.	
	USPD14	US-6,340,742		01-22-2002	Burg, et al.	
	USPD15	US-6,333,031		12-25-2001	Olsson et al.	
	USPD16	US-6,251,864		06-26-2001	Dower et al.	
	USPD17	US-6,211,608		04-03-2001	Raina et al.	
	USPD18	US-6,153,407		11-28-2000	Sytkowski, et al.	
	USPD19	US-6,121,238		09-19-2000	Dower et al.	
	USPD20	US-6,107,272		08-22-2000	Sytkowski	
	USPD21	US-6,103,879		08-15-2000	Chaovapong, et al.	
	USPD22	US-6,083,913		07-04-2000	Dower et al.	
	USPD23	US-6,077,939		06-20-2000	Wej et al.	
	USPD24	US-6,048,971		04-11-2000	Sytkowski, et al.	
	USPD25	US-5,986,047		11-16-1999	Wrighton et al.	
	USPD26	US-5,955,422		09-21-1999	Lin	
	USPD27	US-5,932,546		08-03-1999	Barrett et al.	
	USPD28	US-5,919,758		07-06-1999	Sytkowski	
	USPD29	US-5,869,451		02-09-1999	Dower et al.	
	USPD30	US-5,830,851		11-03-1998	Wrighton et al.	
	USPD31	US-5,773,569		06-30-1998	Wrighton et al.	
	USPD32	US-5,767,078		06-16-1998	Johnson et al.	
	USPD33	US-5,756,349		05-26-1998	Lin	
	USPD34	US-5,747,446		05-05-1998	Sytkowski	
	USPD35	US-5,683,983		11-04-1997	Barrett et al.	
	USPD36	US-5,677,280		10-14-1997	Barrett et al.	
	USPD37	US-5,672,662		09-30-1997	Harris et al.	
	USPD38	US-5,668,110		09-16-1997	Barrett et al.	
	USPD39	US-5,654,276		08-05-1997	Barrett et al.	
	USPD40	US-5,621,080		04-15-1997	Lin	
	USPD41	US-5,618,698		04-08-1997	Lin	
	USPD42	US-5,614,184		03-25-1997	Sytkowski, et al.	
	USPD43	US-5,580,853		12-03-1996	Sytkowski	

Examiner Signature	Date Considered
--------------------	-----------------

(W:\04279\100m213us100663504.DOC (04/23/2006 10:00:00 AM))

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/555,860
Filing Date	November 1, 2005
First Named Inventor	Christopher P. Holmes
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	04279/100M213-US1

Sheet	2	of	4
-------	---	----	---

USPD44	US-5,547,933	08-20-1996	Lin	
USPD45	US-5,468,478	11-21-1995	Saifer et al.	
USPD46	US-5,441,868	08-15-1995	Lin	
USPD47	US-5,378,808	01-03-1995	D'Andrea, et al.	
USPD48	US-5,292,654	03-08-1994	Yoshimura, et al.	
USPD49	US-5,283,317	02-01-1994	Saifer et al.	
USPD50	US-5,278,065	01-11-1994	D'Andrea, et al.	
USPD51	US-5,006,333	04-19-1991	Saifer et al.	
USPD52	US-4,677,195	06-30-1987	Hewick et al.	
USPD53	US-2005/0176627	08-11-2005	Cerami et al.	
USPD54	US-2005/0014240	01-20-2005	Sherman et al.	
USPD55	US-2004/0136952	07-15-2004	Bhaskaran et al.	
USPD56	US-2004/0126361	07-01-2004	Saifer et al.	
USPD57	US-2004/0062746	04-01-2004	Martinez et al.	
USPD58	US-2003/0191291	10-09-2003	Kochendoerfer, et al.	
USPD59	US-2003/0166249	09-04-2003	Williams et al.	
USPD60	US-2003/0134798	07-17-2003	Brines, et al.	
USPD61	US-2003/0125262	07-03-2003	Kiessling, et al.	
USPD62	US-2003/0120045	06-26-2003	Bailon	
USPD63	US-2003/0104988	06-05-2003	Brines, et al.	
USPD64	US-2003/0050269	03-13-2003	Escary	
USPD65	US-2003/0012777	01-16-2003	Sherman et al.	
USPD66	US-2003/0009018	01-09-2003	Maeda et al.	
USPD67	US-2002/0177166	11-28-2002	Guthridge et al.	
USPD68	US-2002/0169128	11-14-2002	Sigounas, et al.	
USPD69	US-2002/0160013	10-31-2002	Olsson et al.	
USPD70	US-2002/0115833	08-22-2002	Burg, et al.	
USPD71	US-2002/0052317	05-02-2002	Itri, et al.	
USPD72	US-2002/0032841	03-28-2002	Panadimitriou, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY			
	FPD1	EP 0 400 472	12-05-1990	Sumitomo Pharmaceuticals Company, Ltd.		
	FPD2	WO 90/12874	11-01-1990	Genetics Institute, Inc.		
	FPD3	WO 92/16221	10-01-1992	Synergen, Inc.		
	FPD4	WO 96/40749	12-19-1996	Johnson & Johnson Corporation		
	FPD5	WO 00/07629	02-17-2000	Mountain View Pharmaceuticals Inc.		
	FPD6	WO 00/12587	03-09-2000	Gryphon Sciences		
	FPD7	WO 01/38342	05-31-2001	Glaxo Group Ltd.		
	FPD8	WO 01/59078	08-16-2001	Mountain View Pharmaceuticals Inc.		

Date	
Considered	

{W:\04279\100m213us1\00663504.DOC: 100m213us1\00663504.DOC}

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substantiate for form 1449A/B/PTO <h2 style="text-align: center;">SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2>				<i>Complete if known</i>	
				Application Number	10/555,860
				Filing Date	November 1, 2005
				First Named Inventor	Christopher P. Holmes
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	04279/100M213-US1

	FPD9	WO 01/91780	12-06-2001	Ortho-McNeil Pharmaceutical, Inc.		
	FPD10	WO 03/002716	01-09-2003	Mountain View Pharmaceuticals, Inc.		
	FPD11	WO 04/030617	04-15-2004	Mountain View Pharmaceuticals, Inc.		
	FPD12	WO 04/060299	07-22-2004	Mountain View Pharmaceuticals, Inc.		
	FPD13	WO 04/060300	07-22-2004	Mountain View Pharmaceuticals, Inc.		
	FPD14	WO 04/100997	11-25-2004	Alfymax, Inc.		

EXAMINER: Initial if reference considered either or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE No.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.93(a)(2)(ii)) because that citation was filed after June 30, 2003 or is available in the IFW. * Applicants unique citation designation number (optional). * See Kinds/Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard 3.3). * For Japanese patent documents, the indication of the year of the year of the Emperor must be provided. * For Chinese patent documents, the Chinese patent number must be provided. * For other patent documents, the patent number must be provided. * If possible, * Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	NPLD1	Abuchowski, A., et al., "Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase," J. Biol. Chem., Vol. 252, pp. 3582-6 (1977)	
	NPLD2	Beauchamp, C.O., et al., "A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin", Anal Biochem., Vol. 131, pp. 25-33 (1983)	
	NPLD3	Chen, R.H., et al., "Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)", Biochem. Biophys. Acta., Vol. 660, pp. 293-8 (1981)	
	NPLD4	El-Sayed et al., "Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium", Pharm. Res., 2001, 18:23-28	
	NPLD5	Francis, G.E., et al., "PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques", Int. J. Hematol., Vol. 68, pp. 1-18 (1998)	
	NPLD6	Gestwicki et al., "Influencing receptor-ligand binding mechanisms with multivalent ligand architecture", J. Amer. Chem. Soc., 2002, 124:14922-14933	
	NPLD7	Johnson, D.L., et al., "Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity", Chem. Biol., Vol. 4, pp. 939-950 (1997)	
	NPLD8	Johnson et al., "Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1", Biochemistry 37: 3699-3710 (1998)	
	NPLD9	Kita, Y., et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma", Dr. Des. Deliv. Vol. 6, pp. 157-67 (1990)	
	NPLD10	Klajnert et al., "Dendrimers: properties and applications", Acta Biochimica Polonica, 2001, 48:199-208	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

W:\04279\100m213us1\00663504.DOC 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/555,860
				Filing Date	November 1, 2005
				First Named Inventor	Christopher P. Holmes
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	04279/100M213-US1

NPLD11	Knauf, M.J., et al., "Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers", J. Biol. Chem., Vol. 263, pp. 15064-70 (1988)	
NPLD12	Lee, J.W., et al., "Reduction of azides to primary amines in substrates bearing labile ester functionality. Synthesis of a PEG-solubilized, "Y"-shaped iminodiacetic acid reagent for preparation of folate-tethered drugs", Org. Lett., Vol. 1, pp. 179-181 (1999)	
NPLD13	Ramakrishnan et al., "Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers", J. Clin. Pharmacol., 2004, 44:991-992	
NPLD14	Saifer, M.G., et al., "Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol", Adv. Exp. Med. Biol. Vol. 366, pp. 377-87 (1994)	
NPLD15	Sasaki, et al., "Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA", Journal of Biological Chemistry 262:12059-12076 (1987)	
NPLD16	Somack, R., et al., "Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 daltons)", Free. Radic. Res. Commun. Vols. 12-13, pp. 553-62 (1991)	
NPLD17	Tsutsumi, Y. et al., "Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity", J. Controlled Release, Vol. 33, pp. 447 (1995)	
NPLD18	Veronese, F. M., "Peptide and protein PEGylation: a review of problems and solutions", Biomaterials 22:405-417 (2001)	
NPLD19	Woler, N.C. et al., "The lectin-binding properties of six generations of mannose-functionalized dendrimers", Organic Letters 4:7-10 (2002)	
NPLD20	Wrighton et al., "Small peptides as potent mimetics of the protein hormone erythropoietin", Science 273:458-463 (1996)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Andrew D. Kosari/	Date Considered	10/23/2009
-----------------------	--------------------	--------------------	------------

(W:\04279\100m213us1\00663504.DOC ~~XXXXXXXXXXXXXXXXXXXX~~)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/